Recombinant biologics for treatment of bleeding disorders

Nature Reviews Drug Discovery

Volumn 3, Issue 8, 2004, Pages 684-694

  Bishop, Paul ^a   Lawson, Jeff ^b  

^a ZYMOGENETICS INC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; FIBRINOGEN; FIBROGAMMIN P; FRESH FROZEN PLASMA; HELIXATE FS; OBI 1; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR; RECOMBINANT PROTEIN;

BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; BLEEDING; HOMEOSTASIS; INCIDENCE; PHYSIOLOGY;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; HEMORRHAGE; HOMEOSTASIS; HUMANS; INCIDENCE; RECOMBINANT PROTEINS;

EID: 4344674120     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1443     Document Type: Review

References (101)

1. Bakaltcheva, I. & Reid, T. Effects of blood product storage protectants on blood coagulation. Transfus. Med. Rev. 17, 263-271 (2003).
2. Sullivan, M. T., McCullough, J., Schreiber, G. B. & Wallace, E. L. Blood collection and transfusion in the United States in 1997. Transfusion 42, 1253-1260 (2002).
3. Varney, S. J. & Guest, J. F. The annual cost of blood transfusions in the UK. Transfus. Med. 13, 205-218 (2003).
4. Lawson, J. H. & Mann, K. G. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J. Biol. Chem. 266, 11317-11327 (1991).
5. Thorelli, E., Kaufman, R. J. & Dahlback, B. Cleavage requirements for activation of factor V by factor Xa. Eur. J. Biochem. 247, 12-20 (1997).
6. Lollar, P., Knutson, G. J. & Fass, D. N. Activation of porcine factor VIII:C by thrombin and factor Xa. Biochemistry 24, 8056-8064 (1985).
7. Loewy, A. G., McDonagh, J., Mikkola, H., Teller, D. C. & Yee, V. C. in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (ed. Colman, R. W.) 233-247 (Lippincott Williams and Wilkins, Philadelphia, 2001).
8. Muszbek, L., Yee, V. C. & Hevessy, Z. Blood coagulation factor XIII: structure and function. Thromb. Res. 94, 271-305 (1999).
9. 2-plasmin inhibitor. J. Biol. Chem. 261, 15591-15595 (1986).
10. Jensen, P. H., Lorand, L., Ebbesen, P. & Gliemann, J. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures. Eur. J. Biochem. 214, 141-146 (1993).
11. Valnickova, Z. & Enghild, J. J. Human procarboxy-peptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J. Biol. Chem. 273, 27220-27224 (1998).
12. Bajzar, L., Manuel, R. & Nesheim, M. E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 270, 14477-14484 (1995).
13. Bajzar, L., Morser, J. & Nesheim, M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271, 16603-16608 (1996).
14. Hogan, K. A., Weiler, H. & Lord, S. T. Mouse models in coagulation. Thromb. Haemost. 87, 563-574 (2002).
15. Lawson, J. H. & Murphy, M. P. Challenges for providing effective hemostasis in surgery and trauma. Semin. Hematol. 41, 55-64 (2004).
16. Harker, L. A. Hemostasis Manual (F. A. Davis, Philadelphia, 1981).
17. Rosner, F. Hemophilia in the Talmud and rabbinic writings. Ann. Intern. Med. 70, 833-837 (1969).
18. McKusick, V. A. The Royal Hemophilia. Sci. Am. 213, 88-95 (1965).
19. Lane, S. Haemorrhagic diathesis. Successful transfusion of bood. Lancet 1, 185-188 (1840).
20. Patek, A. T., FHL. Hemophilia II. Some properties of a substance obtained form normal plasma effective in accelerating the coagulation of hemophilic blood. J. Clin. Invest. 16, 113-134 (1937).
21. Owen, C. A. A History of Blood Coagulation (Mayo Clinic, Rochester, 2001).
22. Bidstrup, B. P., Royston, D., Sapsford, R. N. & Taylor, K. M. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J. Thorac. Cardiovasc. Surg. 97, 364-372 (1989).
23. Mannucci, P. M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90, 2515-2521 (1997).
24. Hewson, J. R. Homeostatic alterations with major trauma. Massive transfusion. Can. Anaesth. Soc. J. 32, 239-240 (1985).
25. Lundblad, R. L. et al. A review of the therapeutic uses of thrombin. Thromb. Haemost. 91, 851-860 (2004).
26. Spotnitz, W. D. Commercial fibrin sealants in surgical care. Am. J. Surg. 182, S8-S14 (2001).
27. Ortel, T. L., Mercer, M. C., Thames, E. H., Moore, K. D. & Lawson, J. H. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann. Surg. 233, 88-96 (2001).
28. Chouhan, V. D. et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb. Haemost. 77, 343-349 (1997).
29. Schoenecker, J. G., Hauck, R. K., Mercer, M. C., Parker, W. & Lawson, J. H. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose α 1-3galactose. J. Clin. Immunol. 20, 434-444 (2000).
30. Evatt, B. L., Farrugia, A., Shapiro, A. D. & Wilde, J. T. Haemophilia 2002: emerging risks of treatment. Haemophilia 8, 221-229 (2002).
31. Godje, O., Haushofer, M., Lamm, P. & Reichart, B. The effect of factor XIII on bleeding in coronary surgery. Thorac. Cardiovasc. Surg. 46, 263-267 (1998).
32. Wozniak, G., Noll, T., Akinturk, H., Thul, J. & Muller, M. Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease. Ann. NY Acad. Sci. 936, 617-620 (2001).
33. Herouy, Y., Hellstern, M. O., Vanscheidt, W., Schopf, E. & Norgauer, J. Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers. Lancet 355, 1970-1971 (2000).
34. Pihusch, R. et al. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut. Br. J. Haematol. 117, 469-476 (2002).
35. Fukui, H. et al. Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schonlein purpura. Japanese Pediatric Group. Thromb. Res. 56, 667-675 (1989).
36. Klein, H. G. Allogeneic transfusion risks in the surgical patient. Am. J. Surg. 170, S21-S26 (1995).
37. Goodnough, L. T., Brecher, M. E., Kanter, M. H. & AuBuchon, J. P. Transfusion medicine. First of two parts - blood transfusion. N. Engl. J. Med. 340, 438-447 (1999).
38. Hebert, P. C. et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N. Engl. J. Med. 340, 409-417 (1999).
39. Vincent, J. L. et al. Anemia and blood transfusion in critically ill patients. JAMA 288, 1490-1507 (2002).
40. Engoren, M. C. et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann. Thorac. Surg. 74, 1180-1186 (2002).
41. Monroe, D. M., Hoffman, M., Oliver, J. A. & Roberts, H. R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br. J. Haematol. 99, 542-547 (1997).
42. Hoffman, M. & Monroe, D. M. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin. Hematol. 38, 6-9 (2001).
43. Butenas, S., Brummel, K. E., Branda, R. F., Paradis, S. G. & Mann, K. G. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 99, 923-930 (2002).
44. Veldman, A., Hoffman, M. & Ehrenforth, S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa, Curr. Med. Chem. 10, 797-811 (2003).
45. Saenko, E. L., Ananyeva, N. M., Shima, M., Hauser, C. A. & Pipe, S. W. The future of recombinant coagulation factors. J. Thromb. Haemost. 1, 922-930 (2003).
46. Toole, J. J. et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312, 342-347 (1984).
47. Lusher, J. M., Arkin, S., Abildgaard, C. F. & Schwartz, R. S. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N. Engl. J. Med. 328, 453-459 (1993).
48. Bray, G. L. et al. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am. J. Hematol. 42, 375-379 (1993).
49. Lee, C. Recombinant clotting factors in the treatment of hemophilia. Thromb. Haemost. 82, 516-524 (1999).
50. Lusher, J. M. Recombinant clotting factors: a review of current clinical status. BioDrugs 13, 289-298 (2000).
51. Bray, G. L. et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 83, 2428-2435 (1994).
52. Mariani, G., Ghirardini, A. & Bellocco, R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb. Haemost. 72, 155-158 (1994).
53. Hedner, U., Glazer, S. & Falch, J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus. Med. Rev. 7, 78-83 (1993).
54. Kurachi, K. & Davie, E. W. Isolation and characterization of a cDNA coding for human factor IX. Proc. Natl Acad. Sci. USA 79, 6461-6464 (1982).
55. Kaufman, R. J., Wesley, L. C., Furie, B. C., Furie, B. & Shoemaker, C. B. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. J. Biol. Chem. 261, 9622-9628 (1986).
56. White, G. C., Beebe, A. & Nielsen, B. Recombinant factor IX. Thromb. Haemost. 78, 261-265 (1997).
57. Shapiro, A. et al. Recombinant Factor IX (rFIX) in the treatment of previously untreated patients (PUPS) with severe or moderately severe hemophilia. Blood 92, A356 (1998).
58. Shapiro, A. D., Gilchrist, G. S., Hoots, W. K., Cooper, H. A. & Gastineau, D. A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb. Haemost. 80, 773-778 (1998).
59. Hagen, F. S. et al. Characterization of a cDNA coding for human factor VII. Proc. Natl Acad. Sci. USA 83, 2412-2416 (1986).
60. O'Hara, P. J. et al. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc. Natl Acad. Sci. USA 84, 5158-5162 (1987).
61. Hedner, U. Dosing with recombinant factor VIIa based on current evidence. Semin. Hematol. 41, 35-39 (2004).
62. Ichinose, A. & Davie, E. W. Primary structure of human coagulation factor XIII. Adv. Exp. Med. Biol. 231, 15-27 (1988).
63. Bishop, P. D. et al. Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae. Biochemistry 29, 1861-1869 (1990).
64. Chung, D. W., Rixon, M. W., Que, B. G. & Davie, E. W. Cloning of fibrinogen genes and their cDNA. Ann. NY Acad. Sci. 408, 449-456 (1983).
65. Prunkard, D. et al. High-level expression of recombinant human fibrinogen in the milk of transgenic mice. Nature Biotechnol. 14, 867-871 (1996).
66. Lord, S. T., Binnie, C. G., Hettasch, J. M. & Strickland, E. Purification and characterization of recombinant human fibrinogen. Blood Coagul. Fibrinolysis 4, 55-59 (1993).
67. Schwarz, H. P. et al. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease. Semin. Thromb. Hemost. 28, 215-226 (2002).
68. Plaimauer, B. et al. Recombinant von Willebrand factor: preclinical development. Semin. Thromb. Hemost. 27, 395-403 (2001).
69. Sultan, Y., Kazatchkine, M. D., Maisonneuve, P. & Nydegger, U. E. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2, 765-768 (1984).
70. Jain, N. FDA recommendations for clinical trails [online] Workshop on FVIII Inhibitors (Meeting minutes, Miller Reporting Co., Inc.) http://www.fda.gov/cber/minutes/fctrviii112103t.pdf (2003).
71. Pasi, K. J. Gene therapy for haemophilia. Br. J. Haematol. 115, 744-757 (2001).
72. Nathwani, A. C., Nienhuis, A. W. & Davidoff, A. M. Current status of gene therapy for hemophilia. Curr. Hematol. Rep. 2, 319-327 (2003).
73. Ratko, T A., Cummings, J. P., Blebea, J. & Matuszewski, K. A. Clinical gene therapy for nonmalignant disease. Am. J. Med. 115, 560-569 (2003).
74. Adis [online; paid-service website] http://www.adis.com (2004).
75. Lind, P. et al. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur. J. Biochem. 232, 19-27 (1995).
76. Eriksson, R. K. et al. The manufacturing process for B-domain deleted recombinant factor VIII. Semin. Hematol. 38, 24-31 (2001).
77. Schwaab, R. et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb. Haemost. 74, 1402-1406 (1995).
78. Drake, T. A., Morrissey, J. H. & Edgington, T. S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am. J. Pathol. 134, 1087-1097 (1989).
79. Rao, L. V. & Rapaport, S. I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 69, 645-651 (1987).
80. Brox, J. H., Osterud, B., Bjorklid, E. & Fenton, J. W. Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets. Br. J. Haematol. 57, 239-246 (1984).
81. Bevilacqua, M. P., Pober, J. S., Majeau, G. R., Cotran, R. S. & Gimbrone, M. A. Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 160, 618-623 (1984).
82. Jaffee, E. in Vascular Medicine (ads Loscalzo, J., Creager, M. A. & Dzau, C. M.) 3-46 (Little, Brown and Co., Boston, 1992).
83. Seyer, J. M. & Kang, A. H. in Vascular Medicine (eds Loscalzo, J., Creager, M. A. & Dzau, C. M.) 47-78 (Little, Brown and Co., Boston, 1992).
84. Hawiger, J. in Vascular Medicine (eds Loscalzo, J., Creager, M. A. & Dzau, C. M.) 205-232 (Little, Brown and Co., Boston, 1992).
85. Colman, R. W. & George, J. N. in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (eds Colman, R. W., Hirsh, J., Marder, V. J., Clowes, A. W. & George, J. N.) 541-596 (Lippincott, Williams & Wilkins, Philadelphia, 2001).
86. Mannucci, P. M. Hemophilia: treatment options in the twenty-first century. J. Thromb. Haemost. 1, 1349-1355 (2003).
87. Dimichele, D., Miller, F. G. & Fins, J. J. Gene therapy ethics and haemophilia: an inevitable therapeutic future? Haemophilia 9, 145-152 (2003).
88. Davie, E. W. & Ratnoff, O. D. Waterfall sequence for intrinsic blood clotting. Science 145, 1310-1312 (1964).
89. Macfarlane, R. G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202, 498-499 (1964).
90. Mann, K. G., Brummel, K. & Butenas, S. What is all that thrombin for? J. Thromb. Haemost. 1, 1504-1514 (2003).
91. Lawson, J. H., Kalafatis, M., Stram, S. & Mann, K. G. A model for the tissue factor pathway to thrombin. I. An empirical study. J. Biol. Chem, 269, 23357-23366 (1994).
92. Osterud, B. & Rapaport, S. I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc. Natl Acad. Sci. USA 74, 5260-5264 (1977).
93. 2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem. J. 265, 327-336 (1990).
94. Lu, G., Broze, G. J. & Krishnaswamy, S. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J. Biol. Chem. (2004).
95. Butenas, S., van 't Veer, C., Cawthern, K., Brummel, K. E. & Mann, K. G. Models of blood coagulation. Blood Coagul. Fibrinolysis 11 (Suppl. 1), S9-S13 (2000).
96. Mann, K. G. Biochemistry and physiology of blood coagulation. Thromb. Haemost. 82, 165-174 (1999).
97. Mann, K. G., van't Veer, C., Cawthern, K. & Butenas, S. The role of the tissue factor pathway in initiation of coagulation. Blood Coagul. Fibrinolysis 9 (Suppl. 1), S3-S7 (1998).
98. Kane, W. H. & Davie, E. W. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 71, 539-555 (1988).
99. Cohen, A. & Kitchens, C. M. in Consultative Hemostasis and Thrombosis (eds Kitchens, C. S., Alving, B. & Kessler, C. M.) 43-56 (W. B. Saunders Co., Philadelphia, 2002).
100. Roberts, H. & Escobar, M. E. in Consultative Hemostasis and Thrombosis (eds Kitchens, C. S., Alving, B. & Kessler, C. M.) 57-74 (W. B. Saunders Co., Philadelphia, 2002).
101. Acharya, S. S., Coughlin, A. & Dimichele, D. M. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J. Thromb. Haemost. 2, 248-256 (2004).